Immunochemotherapy of gastric cancer with levamisole. 1980

H Miwa, and F Ono, and M Moriyama, and T Kobayashi, and T Oka, and K Nakamura, and K Orita

In 156 cases of gastric cancer, levamisole (LMS) was administered at a daily dose of 150 mg for three consecutive days every other week. The administration was started 3 days before operation. This medication was repeated for more than one month. The survival rate up to two years after surgery was studied. The survival rate was not affected in patients with Stage I and II gastric cancer, but in patients with Stage III, the difference in the survival rate between the LMS group and the control group was significantly higher than that in the control group (p less than 0.05). In patients with Stage IV, the survival rate in the LMS group was higher than that in the control group although the difference was not significant. In patients of Stage III and IV, the effect of LMS on the survival rate was highest in cases with curative resection (p less than 0.01). In cases with noncurative resection, the difference between the LMS group and the control group was greatest (24.4%) 12 months after surgery but not significant (p less than 0.5), and also in cases without resection the difference between the two groups was greatest (20.3%) 12 months after surgery but not significant (p less than 0.2).

UI MeSH Term Description Entries
D007978 Levamisole An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6) L-Tetramisole,Levotetramisole,Decaris,Dekaris,Levamisole Hydrochloride,Solaskil,Hydrochloride, Levamisole
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm

Related Publications

H Miwa, and F Ono, and M Moriyama, and T Kobayashi, and T Oka, and K Nakamura, and K Orita
February 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
H Miwa, and F Ono, and M Moriyama, and T Kobayashi, and T Oka, and K Nakamura, and K Orita
December 1983, Acta medica Okayama,
H Miwa, and F Ono, and M Moriyama, and T Kobayashi, and T Oka, and K Nakamura, and K Orita
December 1985, Nihon Gan Chiryo Gakkai shi,
H Miwa, and F Ono, and M Moriyama, and T Kobayashi, and T Oka, and K Nakamura, and K Orita
November 1983, The Japanese journal of surgery,
H Miwa, and F Ono, and M Moriyama, and T Kobayashi, and T Oka, and K Nakamura, and K Orita
January 1984, Cancer immunology, immunotherapy : CII,
H Miwa, and F Ono, and M Moriyama, and T Kobayashi, and T Oka, and K Nakamura, and K Orita
October 1978, Acta medica Okayama,
H Miwa, and F Ono, and M Moriyama, and T Kobayashi, and T Oka, and K Nakamura, and K Orita
May 1994, Lancet (London, England),
H Miwa, and F Ono, and M Moriyama, and T Kobayashi, and T Oka, and K Nakamura, and K Orita
July 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
H Miwa, and F Ono, and M Moriyama, and T Kobayashi, and T Oka, and K Nakamura, and K Orita
September 1984, Problemy tuberkuleza,
H Miwa, and F Ono, and M Moriyama, and T Kobayashi, and T Oka, and K Nakamura, and K Orita
December 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!